Pfizer Inc.

NYSE:PFE   10:44:12 AM EDT
39.69
+0.34 (+0.86%)
Positive Earnings Pre-Announcement

Pfizer Reports Q1 Adjusted EPS $0.93

Published: 05/04/2021 11:40 GMT
Pfizer Inc. (PFE) - Pfizer Reports Strong First-quarter 2021 Results.
Q1 Adjusted Earnings per Share $0.93.
First-quarter 2021 Reported Diluted EPS of $0.86.
First-quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth.
Now Anticipates Revenues of Approximately $26 Billion for Bnt162b2 for FY.
Raises Full-year 2021 Guidance for Revenues to a Range of $70.5 to $72.5 Billion.
Raises Full-year 2021 Guidance for Adjusted Diluted EPS to a Range of $3.55 to $3.65.
Excluding Revenues for Bnt162b2 of $3.5 Billion, Qtrly Revenues Grew 8% Operationally Including a Negative 5% Impact From Pricing.
Enters Into Contracts to Supply Bnt162b2 to Canada and Israel for Periods Beyond 2021.
Maintains Quarterly Dividend for Second-quarter 2021 at $0.39/share.
Pfizer - Continuing to Increase Our Capacity to Supply Urgently-needed Doses of Bnt162b2 to World.
Sees Adjusted Income Before Tax Margin for Bnt162b2 in High-20s As a Percentage of Revenues for FY.
Bnt162b2 Revenue Projection Incorporated Within 2021 Financial Guidance Includes 1.6 Billion Doses That Are Expected to Be Delivered in 2021.
Increasing Its Previous 2021 Financial Guidance for Revenues With Bnt162b2 Contributions Excluded.
Qtrly Worldwide Prevnar 13/prevenar 13 Revenue $1,284 Million Versus $1,450 Million.
Qtrly Worldwide Ibrance Revenue $1,254 Million Versus $1,248 Million.
Q1 Earnings per Share View $0.77, Revenue View $13.51 Billion -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $16.91 Billion
Adjusted EPS is expected to be $0.92

Next Quarter Revenue Guidance is expected to be $18.21 Billion
Next Quarter EPS Guidance is expected to be $0.98

More details on our Analysts Page.